Sumitomo Pharma will issue 51,304,400 new shares at 1,990 yen per share and also offer 7,695,600 shares at the same price. The total amount of funds to be raised is approximately 111.5 billion yen, with applications starting on April 21, 2026.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4506","jir_company_name":"Sumitomo Pharma Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-04-20","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/04\/4506-20260420-01.pdf","jir_short_summary":"Sumitomo Pharma will issue 51,304,400 new shares at 1,990 yen per share and also offer 7,695,600 shares at the same price. The total amount of funds to be raised is approximately 111.5 billion yen, with applications starting on April 21, 2026.","jir_summary":"### Overview of Capital Policy\nSumitomo Pharma Co., Ltd. has decided at the Board of Directors meeting on April 8, 2026, to issue 51,304,400 new shares at 1,990 yen per share through a public offering. These consist of 21,804,400 shares for domestic general offering and 29,500,000 shares for overseas offering. Additionally, 7,695,600 shares will be offered at the same price through an over-allotment. Furthermore, 7,695,600 shares are planned to be issued by a third-party allotment at a payment amount of 1,907.08 yen per share. The total estimated net proceeds from these measures is approximately 111.5 billion yen.\n\n### Use of Proceeds and Future Outlook\nThe funds raised will primarily be allocated to research and development investments. Specifically, 30 billion yen will be dedicated to advancing clinical trials in the oncology field, 10 billion yen for new business development in neurodegenerative diseases and infectious diseases, 10 billion yen for growth in regenerative and cell therapy business, and 10 billion yen for capital expenditures, IT system investments, and strategic partnerships and licensing agreements. Additionally, the funds will be used for repayment of interest-bearing debt to strengthen the financial base. Through these initiatives, Sumitomo Pharma aims for medium- to long-term growth and enhancement of corporate value.","jir_financial_highlights":"Number of new shares issued by public offering: 51,304,400 shares (Unknown)\nIssue price (offering price): 1,990 yen\/share (Unknown)\nPayment amount: 1,907.08 yen\/share (Unknown)\nNumber of shares offered (over-allotment): 7,695,600 shares (Unknown)\nTotal funds to be raised (estimated net proceeds upper limit): 111,565,720,000 yen (Unknown)","jir_category":"","jir_hashtags":"#SumitomoPharma, #CapitalPolicy, #PublicOffering, #JapaneseStocks","jir_key_figures":"Number of new shares issued: 51,304,400 shares (21,804,400 for domestic general offering, 29,500,000 for overseas offering)\nNumber of shares offered (over-allotment): 7,695,600 shares\nTotal estimated net proceeds upper limit: 111,565,720,000 yen","jir_meta_title":"\u3010Sumitomo Pharma\u3011Approximately 111.5 Billion Yen Public Offering\uff5cApril 2026","jir_meta_description":"Sumitomo Pharma will issue 51,304,400 new shares and offer 7,695,600 shares at 1,990 yen per share. The approximately 111.5 billion yen raised will be allocated to research and development and financial soundness enhancement.","jir_og_title":"\u3010Sumitomo Pharma\u3011Approximately 111.5 Billion Yen Public Offering\uff5cApril 2026","jir_og_description":"Sumitomo Pharma is raising about 111.5 billion yen through new share issuance and offering. The funds will be used to strengthen research and development and improve financial health.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":7612,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"capital_policy","footnotes":""},"sector":[],"importance":[],"class_list":["post-41478","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n